ACADIA Pharmaceuticals (ACAD) Q2 2026 earnings summary

Executive summary

• Achieved total revenues of $308 million in Q2 2026, up 17% year-over-year, driven by strong commercial execution for DAYBUE and NUPLAZID.

• DAYBUE net sales reached $125 million, up 30% year-over-year, with significant uptake of the new STIX formulation.

• NUPLAZID net sales were $183 million, up 10% year-over-year, supported by increased demand and expanded field force.

• Net income for Q2 2026 was $32 million, or $0.18 per diluted share, compared to $27 million, or $0.16 per share, in Q2 2025.

• Advanced R&D pipeline with key milestones, including completion of Phase 2 RADIANT enrollment for remlifanserin in Alzheimer's disease psychosis; topline results expected September–October 2026.

Financial highlights

• Q2 2026 total revenues: $308 million, up from $265 million in Q2 2025, representing 17% year-over-year growth (adjusted).

• DAYBUE net sales: $125 million, 30% year-over-year growth, 27% from volume; gross-to-net adjustment 24.4%.

• NUPLAZID net sales: $183 million, 10% year-over-year growth, 8% from volume; gross-to-net adjustment 23.9%.

• R&D expenses: $82 million (vs. $78M prior year); SG&A: $160 million (vs. $134M prior year).

• Cash, cash equivalents, and investment securities totaled $956.5 million at June 30, 2026.

Outlook and guidance

• Raised DAYBUE 2026 net sales guidance to $480M-$510M, reflecting strong U.S. and anticipated EU sales.

• NUPLAZID 2026 net sales guidance unchanged at $760M-$790M.

• Total 2026 revenue expected at $1.24B-$1.3B.

• Lowered R&D expense guidance to $355M-$380M due to milestone shift and portfolio prioritization.

• DAYBUE gross-to-net guidance slightly increased to 23%-25%.